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Background: The current carriage study was set up 
to reinforce surveillance during/after the PCV13-to-
PCVC10 switch in Belgium. Aim: This observational 
study monitored carriage of  Streptococcus pneu-
moniae  (Sp) serotypes, particularly those no longer 
covered (3, 6A, 19A), as well as Haemophilus influen-
zae  (Hi), because PCV10 contains the non-typeable Hi 
protein D. Methods: A total of 2,615 nasopharyngeal 
swabs from children (6–30 months old) attending day 
care were collected in three periods over 2016–2018. 
Children’s demographic and clinical characteristics 
and vaccination status were obtained through a ques-
tionnaire. Sp and Hi were identified by culture and 
PCR. Pneumococcal strains were tested for antimicro-
bial (non-)susceptibility by disc diffusion and sero-
typed by Quellung-reaction (Quellung-reaction and 
PCR for serotypes 3, 6A, 19A). Results: The carriage 
prevalence of Sp (> 75%) remained stable over the suc-
cessive periods but that of Hi increased (87.4%, 664 
Hi-carriers/760 in 2016 vs 93.9%, 895/953 in 2017–
2018). The proportion of non-PCV13 vaccine serotypes 
decreased (94.6%, 438 isolates/463 in 2016 vs 89.7%, 
599/668 in 2017–2018) while that of PCV13-non-PCV10 
vaccine serotypes (3 + 6A + 19A) increased (0.9%, 4 
isolates/463 in 2016 vs 7.8%, 52/668 in 2017–2018), 
with serotype 19A most frequently identified (87.9%, 
58/66 isolates). Non-susceptibility of pneumococci 
against any of the tested antibiotics was stable over 
the study period (> 44%).
Conclusions: During and after the PCV13-to-PCV10 
vaccine switch, the proportion of non-PCV13 sero-
types decreased, mainly due to a serotype 19A car-
riage prevalence increase. These results complement 
invasive pneumococcal disease surveillance data, pro-
viding further basis for pneumococcal vaccination pro-
gramme policy making.
Introduction
Nasopharyngeal carriage of  Streptococcus pneumo-
niae  (Sp) frequently occurs asymptomatically [1-5]. 
Nevertheless, it may evolve to respiratory infections 
such as otitis media and pneumonia or even inva-
sive diseases including bacteraemia and meningitis 
[2,3,5]. Besides the elderly, young children are prone 
to (invasive) pneumococcal diseases ((I)PD) [6-10]. 
Before pneumococcal conjugate vaccines (PCVs) were 
introduced, the global annual number of serious pneu-
mococcal disease cases (pneumonia, meningitis, and 
bacteraemia) in children under 5 years of age was esti-
mated to be 14.5 million [11].
The primary virulence factor of Sp is its polysaccharide 
capsule, which also determines the serotype. More 
than 95 serotypes exist and they vary in their capac-
ity to activate the host immune system and to invade 
[12-15]. PCVs provide direct protection to the vacci-
nated individuals against a number of clinically rel-
evant serotypes [12]. In addition, the wider population 
experiences indirect protection against pneumococcal 
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disease through reduced nasopharyngeal carriage of 
pneumococcal vaccine serotypes (VTs). However, the 
observed magnitude of this indirect effect varies in 
different contexts, and it is eroded by the rising inci-
dence of non-VT-(NVT-)related diseases [16]. Several 
studies on carriage or IPD in the pre- and post-PCV era 
reported on serotype replacement, i.e. VTs being largely 
replaced by NVTs [17,18]. Furthermore, co-colonisation 
with other pathogens such as  Haemophilus influen-
zae  (Hi),  Moraxella catarrhalis  (Mc),  Staphylococcus 
aureus  (Sa), and  Streptococcus pyogenes  (GAS) may 
be changed after PCV-introduction because of mutual 
interactions [19-21].
Belgium initiated a universal childhood PCV-
programme according to a two plus one schedule in 
2007 (at 8 weeks, 16 weeks, and 12 months of age). The 
seven-valent vaccine (PCV7, including serotypes 4, 6B, 
9V, 14, 18C, 19F, 23F) was superseded by the 13-valent 
vaccine (PCV13, including PCV7 serotypes plus 1, 5, 
7F, 3, 6A, 19A, same 2 + 1 schedule) in 2011, which 
was in turn replaced by the 10-valent vaccine (PCV10, 
including PCV7 serotypes plus 1, 5, 7F, same 2 + 1 
schedule) in 2015–2016. The implementation of immu-
nisation programmes constitutes a regional responsi-
bility in Belgium. PCV10 was introduced in the Flemish 
(Northern) region in July 2015 and in the Walloon 
(Southern) region in May 2016 [22]. In the Brussels 
(Capital) region either the Flemish or the Walloon pro-
gramme was followed, depending on the consulting 
physician. The pneumococcal vaccination programme 
rapidly achieved high three-dose coverage in children 
(coverage in Belgium; > 80% in all regions in 2008–
2009 vs > 94% in all regions in 2015–2016 [23-26]) and 
the overall incidence of IPD in Belgium significantly 
decreased after implementation of the vaccination pro-
gramme; post-PCV7 period (2007–2010) vs pre-PCV7 
period (pre 2007): decrease of 35%; post-PCV13 (2015) 
vs PCV7-era (2007–2010): decrease of 42% [22].
The current carriage study was set up to reinforce 
surveillance after the PCV13-to-PCV10 vaccination 
programme switch, in order to monitor the three 
pneumococcal serotypes that were no longer covered 
(3, 6A, 19A), as well as Hi, because PCV10 contains 
the non-typeable Hi (NTHi) protein D. To this end, we 
studied nasopharyngeal carriage of Sp and Hi in chil-
dren between 6 and 30 months of age attending day 
care centres (DCCs) during three consecutive periods 
between 2016 and 2018. High pneumococcal carriage 
rates (range: 21–89%) have been reported in young 
children attending day care [17,27-29]. As such, the 
Table 1
Demographic and clinical characteristics of the healthy child population in day care per period, Belgium, 2016–2018 (n = 760 
children in 2016, 902 in 2016–2017, 953 in 2017–2018)
Characteristics
Healthy children attending day care
Period 1
2016
(N = 760)
Period 2
2016–2017
(N = 902)
Period 3
2017–2018
(N = 953)
p value
chi2 for trend
n %a n %a n %a
Region
Wallonia 353 46.4 287 31.8 282 29.6
  < 0.001Flanders 332 43.7 488 54.1 552 57.9
Brussels 75 9.9 127 14.1 119 12.5
Age in months
6–12 98 12.9 217 24.1 209 21.9
  < 0.00113–24 415 54.6 457 50.7 528 55.4
25–30 247 32.5 228 25.3 216 22.7
Sex Male 387 50.9 455 50.4 469 49.2 0.474
Preterm delivery Yes 60 8.0 71 7.9 78 8.2 0.872
Breastfeedingb Yes 230 30.4 289 32.1 336 35.4 0.026
Parental smokingc Yes 170 22.4 183 20.4 190 20.0 0.231
Siblings Yes 459 62.9 548 61.0 599 63.3 0.813
Common cold symptoms Yes 169 22.4 344 38.2 429 45.0   < 0.001
AOM-historyd Yes 258 34.8 225 25.5 199 21.8   < 0.001
AB < 3 monthse Yes 248 35.4 254 30.5 217 23.5   < 0.001
AB: antibiotic; AOM: acute otitis media.
a Due to missing information on some characteristics for some children, the denominator can at times differ from ‘N’ in the column heading.
b Child was breastfed for more than 6 months.
c At least one parent smokes.
d Child with a history of AOM based on parental recall.
e Use of antibiotics in the 3 months before sampling.
Significant p values (<0.05) are indicated in bold.
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Figure 1
(A) Vaccination status of healthy children in day care (n = 760 in 2016, 902 in 2016–2017, 952a in 2017–2018) and (B) 
proportions of vaccine and non-vaccine serotypesb among Streptococcus pneumoniae carriers (n = 463 carriers in 2016, 613 in 
2016–2017, 668 in 2017–2018), Belgium, 2016–2018
A. Vaccination status of healthy children in day care
B. Proportions of vaccine and non-vaccine serotypesb among Streptococcus pneumoniae carriers
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PCV7-VTsg; 4.3%
non-PCV13-VTsh; 94.6%
PCV13-schedule
PCV10-schedule
PCV7/10/13: 7/10/13-valent pneumococcal conjugate vaccine; STs: serotypes; VTs: vaccine serotypes.
a A total of 952 is used because vaccination status was missing for one of the 953 children in 2017–2018.
b Serotypes are determined by Quellung reaction.
c Incomplete schedule: children who were not or incompletely vaccinated.
d Mixed schedule: children vaccinated with a combination of PCV13 and PCV10.
e STs 3 + 6A + 19A: serotypes included in PCV13, but not in PCV10.
f STs 1 + 5 + 7F: serotypes included in PCV10 but not in PCV7.
g PCV7-VTs: vaccine serotypes included in PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F).
h Non-PCV13-VTs: vaccine serotypes not included in PCV13.
Children in the study were 6–30 months old. Vaccination status was based on vaccination documentation or parental reporting.
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impact of the PCV-programme change was monitored 
in a random sample of this target population, to com-
plement sentinel laboratory-reported IPD-surveillance. 
In this paper, we focus on pneumococcal serotype dis-
tribution and antimicrobial (non-)susceptibility during 
and after the PCV13-to-PCV10 vaccination programme 
switch.
 
Methods
Ethical statement
The current study was in line with the Declaration of 
Helsinki, as revised in 2013. Approval to conduct the 
current study with ID 15/45/471 was obtained from 
the University of Antwerp and University Hospital of 
Antwerp ethics committee (Commissie voor Medische 
Ethiek van UZA/UA) on 30 November 2015.
Study design
The design of this observational study was previously 
described in detail and is summarised here for the com-
plete study period (from Period 1 in 2016 up to Period 3 
in 2017–2018) [30,31].
Nasopharyngeal sampling was performed between 
March and July in Period 1 (2016) and between November 
and March in the consecutive periods (Period 2: 2016–
2017 and Period 3: 2017–2018). Healthy children were 
recruited in DCCs randomly selected over the three 
Belgian regions (Wallonia, Flanders, Brussels), accord-
ing to a population-proportionate distribution at 
regional level based on Belgian Federal Government 
Statistics for the 0–4 year population. In the consecu-
tive periods, 85, 112, and 102 DCCs participated in 
the study, of which 66 DCCs participated in all three 
periods, 44 in two periods, and 24 in one period. A 
population-proportionate sample at the regional level 
was achieved from 2016 to 2017 onwards, after delib-
erate over-recruitment in Wallonia in 2016, in order to 
include a maximum of children who received PCV13 for 
both primary vaccine doses and their booster, since at 
that time, PCV10 was not yet introduced in Wallonia. 
The inclusion criteria were: no treatment with oral 
antibiotics (ABs) in the 7 days before sampling and 
age between 6 and 30 months included. An additional 
age criterion (date of birth before 1 January 2015) was 
applied in Flanders and Brussels for 2016, in order to 
exclusively include children who received PCV13 for 
their primary vaccine doses [30]. In this way, children 
recruited in the first period were on average older 
compared with children recruited in the subsequent 
periods.
Trained nurses and physicians conducted a question-
naire collecting demographic and clinical characteris-
tics of the study participants. The vaccination status 
of the participating child was based on vaccination 
documentation or parental reporting. A single naso-
pharyngeal swab was taken with a flocked nylon fibre 
swab, transported in 1 mL skim milk-tryptone-glucose-
glycerol (STGG) and cultured or stored at − 80 °C within 
24 hours.
Culture analyses
At the National Reference Centre (NRC) for pneumo-
cocci, nasopharyngeal samples were plated on blood 
agar plates for identification of Sp, Mc, Sa, GAS and a 
selective plate for identification of Hi, following over-
night enrichment in brain-heart infusion (BHI) broth 
(entire study period for blood agar plates, 2016 only for 
selective plate) and directly (from 2016–2017 onwards 
for blood agar plates and selective plate). Sp-strains 
were serotyped via Quellung-reaction. Antimicrobial 
(non-)susceptibility of the Sp-strains for erythromycin, 
levofloxacin, penicillin, tetracycline and trimethoprim/
sulfamethoxazole was determined by disc diffusion 
according to the guidelines of Clinical and Laboratory 
Standards Institute (CLSI; 2016 and 2016–2017) [32] and 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST; 2017–2018) [33]. If non-susceptibility 
for penicillin or levofloxacin was identified by disc dif-
fusion, the minimum inhibitory concentration (MIC) was 
determined by Etest (Biomérieux, Craponne, France). A 
MIC of > 0.06 mg/L for penicillin or > 2 mg/L for levofloxa-
cin was interpreted as non-susceptible.
Molecular analyses
DNA was extracted from 200 µL of nasopharyngeal 
sample and tested in real-time PCR targeting  lytA  (for 
Sp) or  P6  (for Hi) [30,34,35]. Real-time PCR was per-
formed for Sp on all samples and for Hi on culture-
negative samples. Samples were classified as positive 
for Sp or Hi when cycle threshold (CT) values were ≤ 40 
or ≤ 35, respectively. LytA-positive samples were pooled 
and screened for presence of the three pneumococcal 
serotypes included in PCV13, but not in PCV10 (PCV13-
non-PCV10-VTs: 3, 6A, 19A). If found positive for sero-
type 3, 6A, or 19A, pooled samples were unpooled and 
positivity of the individual sample was determined. 
Serotype-specific PCRs were performed in a 20 µL 
reaction volume containing 2x Taqman Universal PCR 
Master Mix (Applied Biosystems), 200 nM concentra-
tions of serotype 3 [36], 6A [37], or 19A [36] primers and 
probe and 2 µL of DNA template (pooled PCR-reaction 
contains four times 2 µL of DNA). Samples positive for 
6A real-time PCR were further subjected to 6C real-time 
PCR targeting  wciN  β  to discriminate between sero-
types 6A and 6C [38]. The serotype-specific 6C assay 
was performed as described above, with the excep-
tion that higher primer concentrations of 500 nM were 
used. Amplification was carried out on a StepOnePlus 
Real-Time PCR System (Applied Biosystems, Foster 
City, California, United States) using the following 
cycling parameters: 10 min at 95 °C and 40 cycles of 
15 s at 95 °C and 1 min at 59.5 °C (3, 19A) or 60 °C (6A, 
6C). Serotype-specific PCRs were classified as positive 
when CT values were ≤ 35.
Samples were considered positive for any of the respec-
tive pathogens if either culture or PCR was positive. 
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The presented carriage prevalences of Sp and Hi were 
based on culture and PCR-results, whereas overall 
serotype distribution and antimicrobial (non-)suscep-
tibility were based on Quellung-reaction and culture 
results respectively. The reported carriage prevalence 
of serotypes 3, 6A, and 19A was based on Quellung-
reaction and PCR-results.
Statistics
Sample size and power were calculated using the 
R-package ‘power’ [30]. A sample size of 700 chil-
dren in 2016 and 900 children from the second period 
onwards allows the detection of 4% changes in car-
riage prevalence of Sp-serotypes 19A or 6A over the 
observation period of the study period with 80% power 
and assuming a starting carriage prevalence below 2%.
In IBM SPSS Statistics 25, the chi-squared (Chi2) or 
Fisher’s Exact Test (FET) and the Mann–Whitney U Test 
(MWU) were used to test for significance at a level of 
5%. To identify predictors of carrying Sp, PCV13-non-
PCV10-VTs, and Hi in DCC-children (three periods 
pooled), univariate and multiple binary logistic regres-
sions were performed and adjusted using generalised 
estimating equations (GEEs) with an exchangeable 
correlation structure since 148 children (303 isolates) 
contributed more than one sample over the 3-year 
study period. The GEE model analyses were performed 
using the statistical software R (version 3.6.1) with 
the geepack package (version 1.2–1). Variables with 
a p value < 0.1 in the univariate analysis were included 
in the multiple regression analysis. Since no children 
were sampled in the youngest age category in Flanders 
and in Brussels in 2016, no adjustments can be made 
for the different sampling probabilities in the differ-
ent study years. A continuity correction was applied 
for 95% confidence intervals (95% CI) on proportions. 
Missing values were not replaced.
Results
Study population
Over the three successive periods, nasopharyngeal 
samples from 2,883 children attending DCCs were 
collected. In total, 2,615 samples (760 in 2016, 902 
in 2016–2017, 953 in 2017–2018) – corresponding to 
2,621 pneumococcal isolates, as more than one sero-
type could be found per child (761 in 2016, 904 in 
2016–2017, 956 in 2017–2018), were included in the 
final analyses, i.e. after exclusion of a random selec-
tion of 194 samples collected in 2016–2017 (not ana-
lysed by PCR as a consequence of over-recruitment), 
and after exclusion of 74 samples not fulfilling the 
inclusion criteria regarding age or use of ABs. Of the 
2,615 nasopharyngeal samples, 148 (5.7%) originated 
from children who contributed more than one sample, 
but never in the same period. The univariate and mul-
tiple binary logistic regression models were adjusted 
for this through GEEs with an exchangeable correlation 
structure.
The main demographic and clinical characteristics of 
the child population over the study period are shown 
in  Table 1, with the majority of these characteristics 
remaining similar over the study period. Nevertheless, 
a decreasing trend (p < 0.001) was observed for history 
of acute otitis media (AOM-history) and AB-use in the 
3 months before sampling. The proportions of children 
being breastfed for more than 6 months (p = 0.026) and 
with symptoms (runny nose and/or cough) of common 
cold (p < 0.001) increased over the study period.
As a result of the recruitment strategy to include older 
children in 2016 (mean age: 21.0 months in 2016 vs 
18.4 months in 2016–2017 vs 18.4 months in 2017–
2018), the majority of the Period 1 population was 
vaccinated with PCV13 only (Figure 1: 73.4%; 558/760 
children). The proportion of PCV13-vaccinated children 
decreased over the study period to 2.7% (26/952 chil-
dren; vaccination status was missing for one of the 
953 children in 2017–2018), whereas the proportion 
of PCV10-vaccinated children increased from 0.0% to 
75.9% (723/952 children). 
Figure 2
Carriage prevalencea of Streptococcus pneumoniae and 
Haemophilus influenzae among healthy children in day 
care, Belgium, 2016–2018 (n = 760 children in 2016, 902 in 
2016–2017, 953 in 2017–2018)
Period 1
2016
(n = 760 children)
SpHi-carriersb;
71.2%, 541
Hi-carriersc;
16.2%, 123
Sp-carriersd; 
8.8%, 67 Sp-carriersd; 4.2%, 38 Sp-carriersd; 4.3%, 41
Non-carriers; 1.8%, 17Non-carriers; 2.3%, 21Non-carriers; 3.8%, 29
Hi-carriersc;
22.0%, 198 Hi-carriers
c; 
19.6%, 187
SpHi-carriersb;
71.5%, 645
SpHi-carriersb;
74.3%, 708
Period 2
2016–2017
(n = 902 children)
Period 3
2017–2018
(n = 953 children)
Hi: Haemophilus influenza; Sp: Streptococcus pneumoniae.
a Prevalence was inferred from results of culture and PCR 
combined.
b SpHi-carriers: carriers of Sp and Hi.
c Hi-carriers: carriers of Hi.
d Sp-carriers: carriers of Sp.
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Table 2a
Predictors through binary logistic regression of Streptococcus pneumoniae carriagea (n = 2,615 nasopharyngeal samples) and 
of PCV13-non-PCV10 vaccine serotype carriageb (n = 1,744) among children attending day care (pooled over study periods), 
Belgium, 2016–2018
Number of samples/isolatesc Univariate regression Multiple regression
Characteristic n % OR 95% CId OR 95% CId
Predictors of Sp-carriagea
Study period
2016 760 29.1 REF REF REF REF
2016–2017 902 34.5 0.78 0.62–0.99 0.64 0.47–0.87
2017–2018 953 36.4 0.92 0.73–1.16 0.71 0.52–0.96
Region
Wallonia 922 35.3 REF REF REF REF
Flanders 1,372 52.5 1.29 1.06–1.57 1.09 0.83–1.42
Brussels 321 12.3 1.42 1.04–1.95 1.16 0.81–1.66
Sex
Female 1,304 49.9 REF REF REF REF
Male 1,311 50.1 0.75 0.63–0.91 0.76 0.62–0.93
Common cold symptomse
Yes 942 36.1 REF REF REF REF
No 1,668 63.9 0.65 0.53–0.80 0.64 0.51–0.80
Sa-carriagef
Yes 116 4.4 REF REF REF REF
No 2,499 95.6 1.71 1.14–2.55 1.79 1.13–2.85
Hi-carriageg
Yes 2,402 91.9 REF REF REF REF
No 213 8.1 0.58 0.43–0.79 0.64 0.45–0.90
Mc-carriageg
Yes 2,382 91.1 REF REF REF REF
No 233 8.9 0.26 0.19–0.34 0.31 0.23–0.42
Siblingsh
Yes 1,606 62.4 REF REF REF REF
No 969 37.6 0.72 0.59–0.87 0.73 0.61–0.89
AOM-historyI,j
Yes 682 26.9 REF REF REF REF
No 1,855 73.1 1.36 1.11–1.67 1.14 0.91–1.44
AB: antibiotic; AOM: acute otitis media; CI: confidence interval; Hi: Haemophilus influenza; Mc: Moraxella catarrhalis; OR: odds ratio; PCV: 
pneumococcal conjugate vaccine; PCV13-non-PCV10-VT: vaccine serotypes included in PCV13, but not in PCV10 (serotypes: 3, 6A, 19A); REF: 
reference group for the regression analysis; RSV: respiratory syncytial virus; Sa: Staphylococcus aureus; Sp: Streptococcuspneumoniae.
a Knowledge of Sp carriage was through results of culture and PCR combined.
b Knowledge of PCV13-non-PCV10 vaccine serotype carriage was based on culture or Quellung-reaction results.
c The number of samples was used for the analyses regarding Sp-carriage predictors; the number of isolates was used for the analyses 
regarding PCV13-non-PCV10-VT-carriage predictors.
d Confidence intervals that do not overlap the null value of OR = 1 are indicated in bold.
e Information on common cold symptoms was not available for five children.
f Based on culture-results or Quellung-reaction.
g Based on the combination of culture and PCR-results.
h Information on siblings was not available for 40 children.
i Child with a history of AOM.
j Information on history of AOM was not available for 78 children.
k Use of antibiotics in the 3 months before sampling.
l Information on use of antibiotics in the 3 months before sampling was not available for 157 children.
m Information on vaccination status was missing for one child.
Besides the shown confounders, other variables were assessed, but not significant in univariate analysis: preterm delivery, previous 
hospitalisation, age-appropriate vaccination, carriage of Streptococcus pyogenes (based on culture-results or Quellung-reaction), parental 
smoking, breastfeeding.
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Number of samples/isolatesc Univariate regression Multiple regression
Characteristic n % OR 95% CId OR 95% CId
AB-use < 3 monthsk,l
Yes 719 29.3 REF REF REF REF
No 1,739 70.7 1.79 1.47–2.18 1.63 1.30–2.05
Age (months)
6–12 524 20.0 0.81 0.64–1.03 0.94 0.73–1.22
13–24 1,400 53.5 REF REF REF REF
25–30 691 26.4 0.79 0.64–0.99 0.84 0.65–1.07
Sampled during influenza-peak
Yes 1,072 41.0 REF REF REF REF
No 1,543 59.0 1.23 1.02–1.48 1.01 0.77–1.33
Predictors of PCV13-non-PCV10-VT-carriageb
Study period
2016 463 26.5 REF REF REF REF
2016–2017 613 35.1 1.90 0.59–6.11 1.36 0.36–5.07
2017–2018 668 38.3 9.69 3.48–27.00 5.88 1.56–22.19
Vaccination schedulem
PCV13 486 27.9 REF REF REF REF
PCV10 707 40.6 6.85 2.70–17.35 1.79 0.53–6.01
Incomplete 222 12.7 1.77 0.47–6.64 0.92 0.22–3.87
Mix 328 18.8 3.03 1.02–8.93 1.71 0.50–5.82
Sampled during RSV-peak
Yes 601 34.5 REF REF REF REF
No 1143 65.5 0.512 0.313-0.838 0.88 0.52–1.50
AB: antibiotic; AOM: acute otitis media; CI: confidence interval; Hi: Haemophilus influenza; Mc: Moraxella catarrhalis; OR: odds ratio; PCV: 
pneumococcal conjugate vaccine; PCV13-non-PCV10-VT: vaccine serotypes included in PCV13, but not in PCV10 (serotypes: 3, 6A, 19A); REF: 
reference group for the regression analysis; RSV: respiratory syncytial virus; Sa: Staphylococcus aureus; Sp: Streptococcuspneumoniae.
a Knowledge of Sp carriage was through results of culture and PCR combined.
b Knowledge of PCV13-non-PCV10 vaccine serotype carriage was based on culture or Quellung-reaction results.
c The number of samples was used for the analyses regarding Sp-carriage predictors; the number of isolates was used for the analyses 
regarding PCV13-non-PCV10-VT-carriage predictors.
d Confidence intervals that do not overlap the null value of OR = 1 are indicated in bold.
e Information on common cold symptoms was not available for five children.
f Based on culture-results or Quellung-reaction.
g Based on the combination of culture and PCR-results.
h Information on siblings was not available for 40 children.
i Child with a history of AOM.
j Information on history of AOM was not available for 78 children.
k Use of antibiotics in the 3 months before sampling.
l Information on use of antibiotics in the 3 months before sampling was not available for 157 children.
m Information on vaccination status was missing for one child.
Besides the shown confounders, other variables were assessed, but not significant in univariate analysis: preterm delivery, previous 
hospitalisation, age-appropriate vaccination, carriage of Streptococcus pyogenes (based on culture-results or Quellung-reaction), parental 
smoking, breastfeeding.
Table 2b
Predictors through binary logistic regression of Streptococcus pneumoniae carriagea (n = 2,615 nasopharyngeal samples) and 
of PCV13-non-PCV10 vaccine serotype carriageb (n = 1,744) among children attending day care (pooled over study periods), 
Belgium, 2016–2018
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Carriage prevalence of Streptococcus 
pneumoniae and Haemophilus influenzae
As determined by PCR, very few children carried 
neither Sp, nor Hi, namely 3.8% (29/760 children), 
2.3% (21/902 children), 1.8% (17/953 children) in the 
consecutive periods (Figure 2). The carriage preva-
lence of Sp was stable and high, ranging from 75.7% 
Sp-carriers (683/902 children) in 2016–2017 to 80.0% 
Sp-carriers (608/760 children) in 2016. The carriage 
prevalence of Hi increased significantly (p < 0.001) over 
the study period (87.4% Hi-carriers, 664/760 in 2016 
vs 93.5% Hi-carriers, 843/902 in 2016–2017 vs 93.9% 
Hi-carriers, 895/953, in 2017–2018). Co-colonisation 
with Sp and Hi was frequent and did not change over 
the study period; it ranged from 71.2% (541/760 Sp 
and Hi-carriers) in 2016 to 74.3% (708/953 Sp and 
Hi-carriers) in 2017–2018.
In a multiple regression analysis using pooled data of 
the three periods, positive predictors for Sp-carriage 
among DCC-children (Table 2) were being sampled in 
2016, being female, having symptoms of common cold, 
carrying Hi or Mc, and having siblings, whereas AB-use 
in the 3 months before sampling and carrying Sa were 
associated with a lower likelihood of Sp-carriage. 
Predictors of carrying PCV13-non-PCV10-VTs (based 
on Quellung-reaction) were similarly evaluated using 
binary logistic regression. The only variable that 
remained significant in the multiple regression model 
(Table 2) was study period, indicating higher PCV13-
non-PCV10-VT-carriage in 2017–2018 compared with 
the previous periods. The predictors for Hi-carriage 
that were significant in the multiple regression 
model were having symptoms of common cold (odds 
ratio (OR): 1.63; 95% CI: 1.15–2.31), having siblings 
(OR: 1.45; 95% CI: 1.08–1.94), and carrying Sp (OR: 1.54; 
95% CI: 1.12–2.12), Mc (OR: 1.70; 95% CI: 1.11–2.59), 
or GAS (OR: 8.52; 95% CI: 1.17–62.00) and all of these 
were positive predictors. Being in the age category of 
13–24 months (compared to the two other age catego-
ries: 6–12 months (OR: 0.42; 95% CI: 0.29–0.60) and 
25–30 months (OR: 0.59; 95% CI: 0.42–0.83)), or being 
sampled in 2016–2017 (OR: 2.28; 95% CI: 1.60–3.26) 
or 2017–2018 (OR: 2.26; 95% CI: 1.58–3.24, compared 
with 2016) was associated with a higher likelihood of 
Hi-carriage. Study period and vaccination schedule 
were both included in all regression analyses since 
no collinearity between these variables was observed 
based on a linear regression analysis.
Trends over time in carriage prevalence 
of Streptococcus pneumoniae serotypes
Among the Sp-carriers based on Quellung-results, a 
decreasing trend (p < 0.001) in the proportion of non-
PCV13-VTs (94.6%, 438/463 isolates in 2016 vs 96.9%, 
594/613 isolates in 2016–2017 vs 89.7%, 599/668 iso-
lates in 2017–2018) was accompanied by an increasing 
trend (p < 0.001) in the proportion of PCV13-non-PCV10-
VTs (3 + 6A + 19A: 0.9%, 4/463 isolates in 2016 vs 1.6%, 
10/613 isolates in 2016–2017 vs 7.8%, 52/668 isolates 
in 2017–2018; Figure 1).
Among the latter, serotype 19A was most frequently 
identified (87.9%, 58/66 isolates), followed by sero-
type 3 (10.6%, 7/66 isolates), and serotype 6A, which 
was identified once (1.5%, 1/66 isolates). The Quellung-
reaction and PCR combined results of these serotypes 
among DCC-children’s isolates (Figure 3) showed a sta-
ble carriage prevalence for serotypes 3 (0.5%, 4/761 
isolates in 2016 vs 0.7%, 6/904 isolates in 2016–2017 
vs 0.8%, 8/956 isolates in 2017–2018) and 6A (0.3%, 
2/761 isolates; 0.0%; 0.0%), but a significant increase 
(p < 0.001) was observed for serotype 19A (0.4%, 3/761 
isolates in 2016 vs 1.5%, 14/904 isolates in 2016–2017 
vs 6.4%, 61/956 isolates in 2017–2018).
Based on Quellung-results, non-PCV13-VTs dominated 
Sp-carriage over the entire study period. The serotypes 
23B, 23A, 11A, 15B, 15A, and 10A constituted nearly 
50% of the total non-PCV13-VTs among Sp-carriers in 
all three periods. The separate proportions of the dif-
ferent serotypes identified among Sp-carriers fluctu-
ated over the study period except for three serotypes. 
The proportions of serotypes 19A and 6C consistently 
increased (p < 0.001); from 0.4% (2/463 isolates) in 
2016, to 1.5% (9/613 isolates) in 2016–2017, to 7.0% 
(47/668 isolates) in 2017–2018 for serotype 19A and 
from 0.9% (4/463 isolates) in 2016, to 1.5% (9/613 
isolates) in 2016–2017, to 5.8% (39/668 isolates) in 
2017–2018 for serotype 6C. The proportion of sero-
type 15A consistently decreased (p = 0.042); from 6.7% 
(31/463 isolates) in 2016 to 5.2% (32/613 isolates) in 
2016–2017 to 3.4% (23/668 isolates) in 2017–2018.
Streptococcus pneumoniae and its antimicrobial 
non-susceptibility
The proportion of Sp-strains that were non-suscepti-
ble against any of the five tested antibiotics remained 
stable over the study period (47.1%, 218/463 isolates 
in 2016 vs 49.3%, 299/607 isolates in 2016–2017 
vs 44.6%, 295/662 isolates in 2017–2018), whereas 
non-susceptibility against more than one antibiotic 
increased (18.6%, 86/462 isolates in 2016 vs 26.3%, 
160/609 isolates in 2016–2017, vs 30.5%, 203/666 
isolates in 2017–2018; p < 0.001). Non-susceptibility 
against levofloxacin (cut-off MIC > 2.00 mg/L) was 
inexistent. Non-susceptibility against penicillin (cut-
off MIC > 0.06 mg/L; 13.4%, 62/463 isolates in 2016 
vs 19.2%, 117/609 isolates in 2016–2017 vs 18.5%, 
123/666 isolates in 2017–2018; p = 0.041), erythromy-
cin (17.3%, 80/463 isolates in 2016 vs 16.1%, 98/608 
isolates in 2016–2017 vs 22.0%, 146/664 isolates in 
2017–2018; p = 0.028), and tetracycline (11.7%, 54/463 
isolates in 2016 vs 12.6%, 77/610 isolates in 2016–2017 
vs 20.0%, 133/666 isolates in 2017–2018; p < 0.001) 
increased over the study period, whereas non-suscep-
tibility against trimethoprim/sulfamethoxazole fluctu-
ated over the study period (35.2%, 163/463 isolates 
in 2016 vs 40.3%, 246/610 isolates in 2016–2017 vs 
30.3%, 202/666 isolates in 2017–2018; p = 0.042). 
Nevertheless, trimethoprim/sulfamethoxazole was the 
antibiotic against which most strains (35.1%; 611/1,739) 
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were non-susceptible over the entire study period. The 
serotypes (based on Quellung-reaction) that were most 
often found to be non-susceptible against at least one 
of the tested antibiotics among Sp-carriers are shown 
in Figure 4.
Over the 3-year study period, 23.2% (13/56 19A-strains) 
of the 19A-strains were non-susceptible to more than 
one of the tested antibiotics, whereas two 19A-strains 
(3.6%; 2/56 19A-strains) were non-susceptible to only 
one of the tested antibiotics; erythromycin and trimeth-
oprim/sulfamethoxazole for the respective strains. The 
isolated 19A-strains were most frequently non-sus-
ceptible to erythromycin (93.3%; 14/15 19A-strains), 
followed by tetracycline (86.7%; 13/15 19A-strains), 
trimethoprim/sulfamethoxazole (46.7%; 7/15 
19A-strains), and penicillin (20.0%; 3/15 19A-strains).
Discussion
In this pneumococcal carriage study, we evaluated 
during 3 years any changes in the nasopharyngeal car-
riage prevalence, serotype distribution and antimicro-
bial (non-)susceptibility of Sp in healthy children (aged 
6–30 months) attending DCCs in Belgium, from 2016 
onwards, i.e. during and immediately after a PCV13-to-
PCV10 vaccination programme switch. Common co-col-
onising bacteria were followed as well, with a special 
focus on Hi.
Demographics and clinical characteristics of the study 
population showed higher percentages of common 
cold symptoms in 2016–2017 and 2017–2018 com-
pared with 2016, which might be due to differences 
in sampling period. In 2016, nasopharyngeal samples 
were taken during spring (March–July), whereas the 
subsequent periods encompassed autumn and winter 
(November–March), during which common cold fre-
quently occurs. The higher percentages of AOM-history 
in 2016 compared with the other periods might be due 
to recruitment of (on average) older children in this 
year compared with the subsequent periods and in 
2016 more AB-treatments in the 3 months before sam-
pling were observed. With regard to breastfeeding, it is 
unclear why it is more frequent in 2017–2018 compared 
with the previous periods. It is likely that several fac-
tors contributed to fluctuations in breastfeeding prac-
tices, one of which may be the coinciding extensive 
campaigns (personal communication: Marc Hainaut, 
24 Oct 2018) on the importance of breastfeeding in 
Brussels’ maternity hospitals (in 2017–2018, > 54% of 
the included Brussels children were breastfed for more 
than 6 months).
During the study period, the vaccination status of 
the child populations gradually changed; from mainly 
PCV13-vaccinated children in 2016 to mainly PCV10-
vaccinated children in 2017–2018. Sp-carriage preva-
lence was consistently high (> 75%) over the study 
period. Real-life carriage in DCC might be slightly lower 
since children who were treated with oral ABs in the 
7 days before sampling could not take part in the study.
In contrast, the carriage prevalence of Hi increased sig-
nificantly over the study period (especially in the two 
oldest age categories), despite the increasing number 
of children vaccinated with PCV10, containing the NTHi 
Figure 3
Carriage prevalence of PCV13-non-PCV10 vaccine serotypes 3, 6A, 19Aa, Belgium, 2016–2018 (n = 761 in 2016, 904 in 
2016–2017, 956 in 2017–2018)
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protein D. Other reports also indicated the absence of 
PCV10-induced protection against NTHi [39-41].
The predictors of Sp-carriage identified in our study 
include study period, sex, siblings, common cold 
symptoms, use of antibiotics, Hi-carriage, Mc-carriage, 
Sa-carriage and confirm the findings of other reports 
(besides study period and sex) [5,19,20,42,43].
Based on Quellung-reaction, the proportion of non-
PCV13-VTs decreased significantly over the study 
period, associated with an increase in the proportion 
of the three PCV13-non-PCV10-VTs 3, 6A, 19A (mainly 
19A). We verified for confounders (preterm delivery, 
previous hospitalisation, age-appropriate vaccination, 
GAS-carriage, parental smoking, breastfeeding, and 
the variables shown in Table 2) that could have caused 
increased PCV13-non-PCV10-VT-carriage, but could not 
identify any besides study period, which strengthens 
the hypothesis that the increase was caused by the 
vaccine switch.
Serotype 19A became the most frequent vaccine sero-
type in 2017–2018 and its PCR-based prevalence rose 
from 0.4% in 2016 to 6.4% in 2017–2018. According to 
surveillance data on IPD from the NRC in 2017, serotype 
19A was the second most frequent serotype (after sero-
type 12F) among IPD-isolates of children younger than 
2 years of age. While no increase in serotype 19A fre-
quency had been noted since the introduction of PCV13 
in 2011, an increase was observed for the first time in 
2016, when the frequency changed from 2.1% in 2016 
to 14.2% in 2017 [44]. These findings were confirmed in 
2018, 2 to 3 years after the switch from PCV13 to PCV10 
[45]. In addition to being reported as an invasive sero-
type, 19A has also been reported as a serotype that 
is frequently non-susceptible to antimicrobials [46]. 
Nevertheless, in our study other serotypes dominated 
Figure 4
Non-susceptibility against at least one (n = 463 isolates in 2016, 607 in 2016–2017, 662 in 2017–2018) or more than one 
(n = 462 isolates in 2016, 609 in 2016–2017, 666 in 2017–2018) of the tested antibioticsa and the dominating serotypes among 
strains of Streptococcus pneumoniae non-susceptible to at least one antibioticb, Belgium, 2016–2018
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among the non-susceptible strains (23B, 11A, 15B) as 
they were more prevalent than 19A. Since we excluded 
children who were treated with oral ABs in the 7 days 
before sampling, we possibly missed some non-suscep-
tible strains (including 19A). Besides for serotype 19A, 
a consistently increasing proportion was also observed 
for the carriage of serotype 6C, which increased from 
0.9% in 2016 to 5.8% in 2017–2018. Sweden, where 
PCV13 is used in some regions, while PCV10 is used 
in others, also reported an increase in serotype 6C in 
PCV10-regions [47]. This could have implications for the 
non-vaccinated elderly, as reported in Finland, where 
serotypes 19A and 6C are frequently isolated from IPD 
in adults older than 65 years [48].
Our results should be interpreted in the context of sev-
eral limitations. First, a decreasing age trend was intro-
duced by recruiting older children in 2016 in order to 
include a maximum of children vaccinated with PCV13 
and for the same reason, Wallonia was over-recruited 
in 2016. Since this is intrinsic to our study design, we 
cannot adjust for this: the sampling probabilities did 
not allow re-weighting for any of the analyses because 
no children were sampled in the youngest age category 
in Flanders and in Brussels in 2016.
Furthermore, the Sp-carriage prevalence was sta-
ble within the different age categories (6–12, 13–24, 
25–30 months) over the study period, but the Hi-carriage 
prevalence in the two oldest age categories increased 
over the study period. Second, we over-recruited in 
Wallonia in 2016 to enlarge the PCV13-vaccinated pop-
ulation, but in the first season no regional differences 
in overall Hi-carriage or pneumococcal carriage, and 
vaccine type carriage were found. Third, a comparative 
analysis based on the children’s vaccination schedule 
was not performed due to the small size of these sub-
populations in either 2016 (few PCV10-vaccinated chil-
dren) or 2017–2018 (few PCV13-vaccinated children). 
Finally, a 3-year study period is short to completely 
exclude natural fluctuations in the carriage prevalence 
of specific serotypes; a follow-up study should confirm 
whether or not a new equilibrium is reached.
Despite these limitations, our study allowed to moni-
tor the impact of the PCV13-to-PCV10 vaccine switch on 
nasopharyngeal carriage, serotype distribution, and 
antimicrobial (non-)susceptibility of Sp. This is a com-
plementary activity to the analysis of IPD-surveillance 
data, thus providing further basis for policy making on 
pneumococcal vaccination programme options.
Conclusions
As the proportion of children vaccinated exclusively 
with PCV10 increased, the proportion of the serotypes 
not included in PCV13 decreased over the 3-year study 
period, mainly due to an increase in the carriage preva-
lence of serotype 19A.
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